Abstract
Central nervous system (CNS) metastases constitute a challenge for the design of anaplastic lymphoma kinase (ALK) fusion-positive lung cancer trials. The ASCEND-7 study of ceritinib demonstrates the feasibility of broadening CNS eligibility criteria to include symptomatic brain and leptomeningeal disease and highlights design features that contemporary trials will need to incorporate. See related article by Chow et al., p. 2506.
©2022 American Association for Cancer Research.
Publication types
-
Editorial
-
Research Support, Non-U.S. Gov't
-
Research Support, N.I.H., Extramural
-
Comment
MeSH terms
-
Anaplastic Lymphoma Kinase
-
Brain / pathology
-
Carcinoma, Non-Small-Cell Lung* / pathology
-
Central Nervous System
-
Central Nervous System Neoplasms* / diagnosis
-
Humans
-
Lung Neoplasms* / pathology
-
Protein Kinase Inhibitors / therapeutic use
-
Pyrimidines
-
Receptor Protein-Tyrosine Kinases
-
Sulfones
Substances
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Sulfones
-
Anaplastic Lymphoma Kinase
-
Receptor Protein-Tyrosine Kinases
-
ceritinib